drugset / Trial / NCT06832085

Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation

NCT06832085

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this vanguard trial is to test whether clients of Sun Life are willing to join in a quit smoking program that offers counselling and tobacco cessation products to all participants over a 12-month period. The study team will track the safety and usage of 3 types of cessation products as well as the effectiveness of a virtual pharmacy (i.e. cessation products delivered to participants directly from a pharmacy). The goal is to recruit a minimum of 150 participants for this Vanguard phase. The purpose of this study is to look at 3 approved smoking cessation products used in combination with counselling and virtual delivery of the smoking cessation products. The goal is to track product usage, safety, and adherence (how much of the products people use and how many counselling sessions they complete). Within the study there will also be an observational group who will not receive study medication but who will receive free virtual coaching and follow-up for smoking cessation and complete study questionnaires.

Timeline

Start
2025-04-30
Primary completion
2027-04-30
Completion
2027-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cytisinicline Small molecule 3 mg Oral
Comparator Nicotine Unknown Topical
Comparator Varenicline Small molecule 1 mg Oral

Indications

No indication recorded.